U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C7H14NO5P
Molecular Weight 223.1635
Optical Activity ( + )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SELFOTEL, (+)-

SMILES

OC(=O)[C@@H]1C[C@H](CP(O)(O)=O)CCN1

InChI

InChIKey=LPMRCCNDNGONCD-RITPCOANSA-N
InChI=1S/C7H14NO5P/c9-7(10)6-3-5(1-2-8-6)4-14(11,12)13/h5-6,8H,1-4H2,(H,9,10)(H2,11,12,13)/t5-,6+/m1/s1

HIDE SMILES / InChI
(+)-selfotel ((+)-CGS-19755) is an enantiomer of selfotel, a competitive antagonist at N-methyl-D-aspartate (NMDA)-preferring receptors. The inhibition of NMDA-evoked ACh release from rat striatal slices is stereospecific, with the (+)-enantiomer less potent than the (-)-enantiomer.

CNS Activity

Approval Year

Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
20676 ng/mL
2 mg/kg single, intravenous
dose: 2 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SELFOTEL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
31622 ng × h/mL
2 mg/kg single, intravenous
dose: 2 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SELFOTEL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2 h
2 mg/kg single, intravenous
dose: 2 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SELFOTEL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: stroke
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 6
Sources:
Other AEs: Agitation, Confusion...
Other AEs:
Agitation (66.7%)
Confusion (50%)
Delirium (33.3%)
Paranoid reaction (50%)
Coordination abnormal (16.7%)
Aphasia (16.7%)
Hallucination (50%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Aphasia 16.7%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: stroke
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 6
Sources:
Coordination abnormal 16.7%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: stroke
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 6
Sources:
Delirium 33.3%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: stroke
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 6
Sources:
Confusion 50%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: stroke
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 6
Sources:
Hallucination 50%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: stroke
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 6
Sources:
Paranoid reaction 50%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: stroke
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 6
Sources:
Agitation 66.7%
2 mg/kg single, intravenous
Highest studied dose
Dose: 2 mg/kg
Route: intravenous
Route: single
Dose: 2 mg/kg
Sources:
unhealthy, ADULT
n = 6
Health Status: unhealthy
Condition: stroke
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 6
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Yohimbine-induced seizures involve NMDA and GABAergic transmission.
1992 Apr
Glutamatergic antagonism: effects on lidocaine-induced seizures in the rat.
1994 Oct
The 26th Congress of the Scandinavian Society of Anaesthesiology and Intensive Care Medicine, Tromso, Norway, 13-17 June 2001.
2001 Aug
Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?
2002 Oct
NMDA-evoked consumption and recovery of mitochondrially targeted aequorin suggests increased Ca2+ uptake by a subset of mitochondria in hippocampal neurons.
2003 Dec 12
Lessons from epidemiologic studies in clinical trials of traumatic brain injury.
2004
Acute nociceptive somatic stimulus sensitizes neurones in the spinal cord to colonic distension in the rat.
2004 Oct 1
Cognitive effects of dopaminergic and glutamatergic blockade in nucleus accumbens in pigeons.
2005 Aug
Homocysteine, a risk factor for atherosclerosis, biphasically changes the endothelial production of kynurenic acid.
2005 Jul 11
Severe brain injury ICU outcomes are associated with Cranial-Arterial Pressure Index and noninvasive Bispectral Index and transcranial oxygen saturation: a prospective, preliminary study.
2006
The NMDA receptor antagonist CGS 19755 disrupts recovery following cerebellar lesions.
2006
NMDA receptor activity in learning spatial procedural strategies II. The influence of cerebellar lesions.
2006 Oct 16
Intracranial pressure monitoring in intensive care: clinical advantages of a computerized system over manual recording.
2007
Increased cerebral oxygen consumption in Eker rats and effects of N-methyl-D-aspartate blockade: Implications for autism.
2007 Aug 15
Molecular mechanisms of traumatic brain injury: the missing link in management.
2009 Feb 2
NMDA-mediated modulation of dopamine release is modified in rat prefrontal cortex and nucleus accumbens after chronic nicotine treatment.
2009 Jan
Cerebral vasospasm following traumatic subarachnoid hemorrhage.
2009 Nov
Resistin is associated with mortality in patients with traumatic brain injury.
2010
Integrative emphases on intimate, intrinsic propensity/pathological processes--causes of self recovery limits and also, subtle related targets for neuroprotectionl pleiotropicity/multimodal actions, by accessible therapeutic approaches--in spinal cord injuries.
2010 Jul-Sep
Patents

Patents

Sample Use Guides

Two pivotal phase 3 ischemic stroke trials tested the hypothesis, by double-blind, randomized, placebo-controlled parallel design, that a single intravenous 1.5 mg/kg dose of Selfotel, administered within 6 hours of stroke onset, would improve functional outcome at 90 days, defined as the proportion of patients achieving a Barthel Index score of >/=60. The trials were performed in patients aged 40 to 85 years with acute ischemic hemispheric stroke and a motor deficit.
Route of Administration: Intravenous
In Vitro Use Guide
Selfotel (CGS 19755 [cis-4-phosphonomethyl-2-piperidine carboxylic acid]) was found to be a potent, stereospecific inhibitor of N-methyl-D-aspartate (NMDA)-evoked, but not KCl-evoked, [3H] acetylcholine release from slices of the rat striatum. The concentration-response curve to NMDA was shifted to the right by CGS 19755 (pA2 = 5.94), suggesting a competitive interaction with NMDA-type receptors.
Name Type Language
SELFOTEL, (+)-
Common Name English
CGS-20282
Code English
2-PIPERIDINECARBOXYLIC ACID, 4-(PHOSPHONOMETHYL)-, (2S,4R)-
Systematic Name English
(2S,4R)-4-(PHOSPHONOMETHYL)-2-PIPERIDINECARBOXYLIC ACID
Common Name English
Code System Code Type Description
FDA UNII
N0905W44Y3
Created by admin on Sat Dec 16 08:22:50 UTC 2023 , Edited by admin on Sat Dec 16 08:22:50 UTC 2023
PRIMARY
CAS
113229-62-2
Created by admin on Sat Dec 16 08:22:50 UTC 2023 , Edited by admin on Sat Dec 16 08:22:50 UTC 2023
PRIMARY
PUBCHEM
68736
Created by admin on Sat Dec 16 08:22:50 UTC 2023 , Edited by admin on Sat Dec 16 08:22:50 UTC 2023
PRIMARY